Myeloablative Transplantation Using Either Cord Blood or Bone Marrow Leads to Immune Recovery, High Long-Term Donor Chimerism and Excellent Survival in Chronic Granulomatous Disease
Multicenter Biologic Assignment Trial Comparing Reduced-Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care In Patients Aged 50 to 75 with Intermediate-2 and High-Risk Myelodysplastic Syndrome*
Predictive Value of C-peptide Measures for Clinical Outcomes of Islet Transplantation in Type 1 Diabetes: a Report from the Collaborative Islet Transplant Registry (CITR)